Recent developments include the company's Nasdaq debut and progress updates on its Nu-3 product candidate for diabetic foot ulcers.

• Lakewood-Amedex debuted on Nasdaq under the ticker LABT in April 2026, with the stock price increasing following the listing [N2].
• In May 2026, the company provided a progress update on its Nu-3 product candidate targeting diabetic foot ulcers, with the stock price declining following the announcement [N1].
• Dr. Joseph Tucker was appointed to the Board of Directors in April 2026, bringing significant biotechnology leadership experience [S1].

The company is advancing its Nu-3 product candidate for diabetic foot ulcers, a significant medical need. The addition of an experienced biotech executive to the board may enhance strategic execution and capital raising capabilities.

The company has limited liquidity with a current ratio of 0.02 and reported a net loss in the latest quarter. The lack of detailed risk disclosures and limited operational transparency increase uncertainty about business sustainability and execution.

The company is in early-stage biotherapeutics development with limited disclosed competitive advantages or proprietary technology details. Its moat is not clearly defined in public disclosures.

• Liquidity Risk: The company has a very low current ratio of 0.02 and a cash ratio of 0 as of March 31, 2026, indicating potential challenges in meeting short-term obligations [S1].
• Operational and Execution Risk: Limited public disclosure on product pipeline progress and business operations increases uncertainty about the company's ability to execute its development plans effectively.
• Market and Regulatory Risk: As a biotechnology company developing therapeutic products, the company faces inherent risks related to regulatory approvals, clinical trial outcomes, and market acceptance.

• Lakewood-Amedex Biotherapeutics Inc. is a publicly listed company on Nasdaq under the ticker LABT [N2].
• The company is classified as an emerging growth company and is incorporated in the United States, specifically Florida [S1].
• Dr. Joseph Tucker was appointed to the Board of Directors on April 24, 2026, bringing extensive experience in biotechnology leadership and capital raising [S1].
• Dr. Tucker's compensation includes quarterly payments in common stock and warrants to purchase shares at $10.00 per share, vesting over four tranches [S1].
• The company is developing Nu-3, a product candidate for diabetic foot ulcers, with recent progress updates provided in May 2026 [N1].
• Financial snapshot as of March 31, 2026, shows cash and equivalents of $11,709, current assets of $50,626, and current liabilities of $3,027,696, resulting in a current ratio of 0.02 and a cash ratio of 0 [S1].
• The company reported a net loss of $923,291 and basic and diluted EPS of -$0.20 for the quarter ended March 31, 2026 [S1].
• The company does not disclose detailed risk factors in its filings due to smaller reporting company status [S1].